INTRODUCTION

Cervical cancer is the second most common cancer among women in the world, and a leading cause of cancer mortality, affecting mainly the under-served populations of sub-Saharan Africa, Central and Latin America, and South-Central Asia (Ferlay et al., 2010a,b). Clinical staging of cervical cancer is based on the International Federation of Gynecology and Obstetrics (FIGO) system, which was revised in 2009 (Pecorelli et al., 2009). This staging system is based on physical examination and inspection with scintigraphic radiographic evaluation, aiming to be easily introduced in non-developed nations with limited access to imaging studies. However, compared with surgical staging, clinical examinations alone can under-stage cervical cancer in 20–30% of stage IB and up to 64% of stage IIB patients (Lagasse et al., 1980). Improvements in tumor staging by imaging modalities, such as computed tomography (CT), magnetic resonance imaging (MRI), and fluorine-18-labeled fluorodeoxyglucose positron emission tomography (FDG-PET) can significantly improve treatment decisions and the accuracy of highly precise radiotherapy.

Locally advanced cervical cancer is treated with chemoradiotherapy (CRT), which has shown to improve local control and survival. Nevertheless, increasingly more radio- and chemo-resistant tumors still recur. New research strategies have focused on the development of tumor biomarkers aiming to combine CRT with new molecular targets. In this setting FDG-PET/CT and other molecular tracers might help to identify more aggressive tumors.

Stage IIIb and IV tumors.

PET-CT is useful for assessing treatment response 3 months after completing concurrent chemoradiotherapy (CRT) and predicting long-term survival, and in suspected disease recurrence. In the era of image-guided adaptive radiotherapy, accurately defining disease areas is critical to avoid irradiating normal tissue. Based on additional information provided by FDG-PET, radiation treatment volumes can be modified and higher doses to FDG-positive lymph nodes safely delivered. FDG-PET/CT has been used for image-guided brachytherapy of FDG-avid tumor volume, while respecting low doses to bladder and rectum. Despite survival improvements due to CRT in cervical cancer, disease recurrences continue to be a major problem. Biological rationale exists for combining novel non-cytotoxic agents with CRT, and drugs targeting specific molecular pathways are under clinical development. The integration of these targeted therapies in clinical trials, and the need for accurate predictors of radio-curability is essential. New molecular imaging tracers may help identifying more aggressive tumors. 64Cu-labeled diacetyl-di(N(4)-methylthiosemicarbazone) is taken up by hypoxic tissues, which may be valuable for prognostication and radiation treatment planning. PET/CT imaging with novel radiopharmaceuticals could further impact cervical cancer treatment as surrogate markers of drug activity at the tumor microenvironment level. The present article reviews the current and emerging role of PET/CT in the management of cervical cancer.

Keywords: cervical cancer, positron emission tomography, Fluorodeoxyglucose F18, radiation therapy, Planning, Treatment Volumes
Fluorine-18-labeled fluoro-2-deoxy-D-glucose positron emission tomography – computed tomography can also be used in the initial evaluation of the primary tumor, which is usually FDG-avid, and can provide additional information regarding involved lymph nodes, and distant metastases.

Wong et al. (2004) reported a series of 41 patients with cervical cancer who had a FDG-PET in the initial work-up. Their conclusion was that the PET was able to detect 100% of primary cervical tumors. Another study, which included 60 patients, and reported lower sensitivity of FDG-PET for patients with cervical cancer stage 1A2–2A, but this study was performed without combined CT (Chou et al., 2006). It has been demonstrated that PET/CT has a higher accuracy than separate PET and CT scans read side-by-side (Metser et al., 2007).

The degree of FDG-activity in the primary tumor, as measured by the maximum standardized uptake value (SUVmax), is a predictive biomarker of lymph node status and disease outcome (Kidd et al., 2007). Cervical cancer histology and tumor differentiation has shown to affect FDG uptake. In a study performed by Kidd et al. (2009), 240 women with cervical cancer stage IB2–IVB were evaluated with pre-treatment FDG-PET/CT. In this study, the mean SUVmax was significantly different between well differentiated vs. poorly differentiated tumors (p = 0.047). Squamous vs. non-squamous tumors demonstrated a significant difference in SUVmax (p = 0.015). The influence of tumor volume as a prognostic factor in cervical cancer has been previously established (Eifel et al., 1994; Fyles et al., 1995; Perez et al., 1998). Poor regression of initial tumor volume has been found by several groups to confer a poor overall survival. Mayr et al. (2002) used MRI scans to evaluate tumor regression at 40–50 Gy of external beam RT combined with chemotherapy in 34 cervical cancer patients. Regression to less than 20% of residual tumor volume resulted in a cumulative incidence of local recurrence of 9.5 vs. 77% in patients with more than 20% residual volume (p < 0.001).

In line with these results, a recent prospective study that included 32 patients who underwent FDG-PET/CT during the course of radiotherapy showed that after 19.8 Gy of external beam radiotherapy, the mean physiologic tumor volume was reduced from 102 to 72 cm³, representing a 29% reduction in volume (Lin et al., 2006). After an additional 13 Gy from high dose rate (HDR) brachytherapy, the mean volume was reduced to 15.4 cm³ and subsequently to 8.6 cm³. Patients with residual disease after 3 months of CRT had a worst outcome. This study has important implications for the use of image-guided adaptive radiotherapy. For example, patients with important tumor response during the course of treatment can potentially benefit from dose-volume modifications, which might help to reduce acute and late toxicity, whilst patients with persistent disease might be candidates for other research strategies such as adjuvant chemotherapy or evaluation of new biological therapy (Gaffney, 2005; Herrera et al., 2006; Duenas-Gonzalez et al., 2011; Townsley et al., 2011; Gaffney et al., 2012; Schellfer et al., 2012).

A recent publication evaluating 47 patients with stage IB–IV cervical cancer compared quantitative and qualitative discrepancies between MRI and PET/CT using a conformity index and an overlap factor (Ma et al., 2011). Tumor volume measurements were not statistically different with either modality, although the study shows that for tumors larger than 60 cm³ the overlap factor was 0.68, indicating 32% discordance, and for smaller tumors the overlap factor fell to 0.28, indicating 72% discordance. The authors concluded that MRI and PET/CT show a similar performance in evaluating tumor volume but that the location of the tumor can vary significantly between these two imaging modalities possibly due to tumor and organ movement between scans. This has important implications for contouring the gross tumor volume (GTV) in radiotherapy. In our institution, both imaging modalities are fused in the planning CT. To delineate tumor GTV on fused PET/CT-planning CT, we use a method of automatic 3D volume segmentation of the functional image based on the relationship between source to background ratio. The lesion is segmented based on a given level of radio-activity from the functional image (Daisne et al., 2003). In our clinic, we have chosen Velocity Advanced Image Software (Atlanta, USA), a commercially available software, which provides a different algorithm to automatically segment the region of interest based on the principles previously described (Figure 1). Both MRI-GTV and automated segmented FDG-PET/CT-GTV are then joining for accurate delineation of the final GTV.

**NODAL STAGING**

Nodal status can significantly influence disease outcome with 90% overall survival in patients with small tumors and negative lymph nodes, and less than 50% in patients with positive pelvic lymph nodes. Patients with positive para-aortic lymph lymph nodes have a bleak prognosis with an overall survival of 20–30% after 5 years. The evaluation of nodal status can therefore have a tremendous impact in the treatment planning with radiotherapy. For example, the presence of metastatic lymph nodes in the pelvis or para-aortic area can lead to plan an intensity-modulated radiation therapy (IMRT)–integrated boost with dose escalation on that involved area (Kidd et al., 2010a, Figures 2A,B). Tsai et al. (2004) found that 28% of patients had their treatment modified due to additional PET findings in untreated cervical cancer with MRI-defined pelvic node metastasis.

Positron emission tomography – computed tomography is more accurate than CT for evaluating lymph node staging, although the sensitivity and specificity of FDG-PET/CT are variable depending on the stage of the disease (Kidd et al., 2010a). In early stage disease PET/CT has a sensitivity of 53–73%, and a specificity of 90–97% for the detection of lymph node involvement (Reinhardt et al., 2001; Roh et al., 2005; Wright et al., 2005; Chou et al., 2006; Sironi et al., 2006).

In more advanced disease (>IB2), the sensitivity for detecting para-aortic lymph node involvement increases to 73% with a specificity of 99%. PET sensitivity has been reported to be superior to MRI. Sugitani et al. (1999) reported 86% FDG-PET sensitivity for pelvic and para-aortic lymph node metastasis, compared with a CT sensitivity of 57% in a series of 21 patients with advanced cervical cancer.Rose et al. (1999) reported a study of locally advanced cervical cancer assessed by PET before surgical staging, in which FDG-PET had a sensitivity of 73%, a specificity of 92%, a positive predictive value (PPV) of 73% and a negative predictive value (NPV) of 92% for para-aortic lymph node metastasis.
FIGURE 1 | A 62-year-old woman with a FIGO IIB cervical cancer, treated with concomitant cisplatin-based chemotherapy and radiotherapy. Image shows the radiotherapy contouring process on fused planning-CT and FDG-PET/CT images. Contouring is done on VelocityAI Software ( Velocity, Atlanta, GA, USA), based on a method of automatic 3D volume segmentation of the functional image, that depends on the relationship between source to background ratio.

FIGURE 2 | (A) A 48-year-old lady with a cervical cancer stage FIGO IIB, presenting with multiple positive lymph nodes in continuity located in the bilateral iliac and para-aortic regions on FDG PET/CT. She was treated with chemo-radiotherapy using helical TomoTherapy. (B) Three level of radiotherapy dose were designed and treated simultaneously. Pelvis and para-aortic areas received 44.8 Gy/1.6 Gy in 28 fractions. The PAO and pelvis regions surrounding positive nodes but without metabolic uptake were treated with 50.4 Gy/1.8 Gy in 28 fractions. Positive FDG PET/CT lymph nodes were treated with a simultaneous integrated boost up to 59.36 Gy/2.12 Gy in 28 fractions. Scale dose bending shows the 95% of the dose.

In the series of the Gustave Roussy Institute, histological results of complete para-aortic lymphadenectomy were reported in patients treated for stage IB2/IIB cervical carcinoma who had no para-aortic uptake on FDG-PET/CT: three out of thirty-eight patients had histologically proven para-aortic involvement (metastatic nodes with capsular rupture in the para-aortic area), leading to a NPV of 92% for para-aortic nodal involvement (Boughanim et al., 2008).

Grigsby et al. (2001) retrospectively studied 101 patients before primary CRT. CT scan demonstrated abnormal pelvic lymph nodes in 20% and para-aortic lymph nodes in 7%, while PET/CT detected abnormal FDG uptake in the pelvic lymph nodes in 67%, in the para-aortic lymph nodes in 21% and in the supravacular lymph nodes in 8%. The 2-year progression-free rates were 64% for CT (−) PET (−), 18% for CT (−) PET (+); and 14% for CT (+) PET (+) (p < 0.001). A recent update of that study which finally enrolled 560 patients treated with surgery alone, surgery and post-operative radiotherapy, or definitive CRT, showed that in 47% of patients, lymph node involvement had been shown on FDG-PET/CT at diagnosis (Kidd et al., 2010a). The frequency of lymph node metastasis was similar to that in historical surgical series and increased according to the clinical stage. Patients with PET-positive lymph nodes had significantly worse disease-specific survival than those with PET-negative lymph nodes (p < 0.001). Disease-specific survival was stratified into distinct groups based on the most distant level of PET-detected nodal disease (axial, pelvic, para-aortic, or supravacular). The hazard ratios for disease recurrence increased incrementally based on the most
distant level of nodal disease: pelvic 2.4 (95% CI, 1.6–3.5), para-aortic 5.9 (95% CI, 3.8–9.1), and supraclavicular 30 (95% CI 17–55).

Most significantly, in a subgroup of 85 patients with positive FDG-PET/CT lymph nodes, the lymph node SUVmax was predictive of treatment response, risk of pelvic disease recurrence, disease-specific survival, and overall survival. The SUVmax at the level of the lymph nodes was found to be predictive of persistent disease in the pelvic lymph node region after treatment, and more than 80% of patients who demonstrated persistent disease in their post-treatment FDG-PET/CT were eventually confirmed to have a pelvic disease recurrence (Kidd et al., 2010b).

These results have important implications for treatment decisions, and raise the question if lymphadenectomy staging is still necessary. Narayan et al. (2001) compared PET with MRI and assessed whether using either of these methods would avoid surgical staging in 27 patients with locally advanced cervical carcinoma assigned to receive local radiotherapy. PET demonstrated sensitivity superior to MRI, and had a PPV of 98% to detect para-aortic lymph node metastasis. However, small volume micro-metastatic disease was still missed on PET. They recommended para-aortic lymphadenectomy in all patients with positive pelvic nodes on PET.

In our institution, independently of the FDG-PET status, we routinely perform lymphadenectomy as a standard approach. This has the advantage of detecting the 5–8% positive lymph nodes not visible on PET allowing a better treatment assignment of either surgery or CRT for early stage disease.

EVALUATION OF TREATMENT RESPONSE AND DISEASE RECURRENCE

One third of patients with locally advanced cervical cancer will have disease recurrence, usually within 2 years of completing treatment. Predictors of disease recurrence include clinical stage, lymph node status at diagnosis, and tumor response after treatment. After CRT as definitive treatment of locally advanced cervical cancer there is sufficient evidence to support the use of PET/CT for the assessment of treatment response. The presence of FDG activity (either persistent or new) can predict survival outcome. A study in which FDG-PET/CT was performed 3 months after completion of treatment showed that a metabolic response was predictive of long-term survival, with a 3-year survival rate of 78% in patients with a complete metabolic response, 33% in patients with a partial metabolic response, and 0% in those with progressive disease (Schwarz et al., 2007). Multivariate analysis in that study showed that post-treatment response and lymph node status at diagnosis were the only accurate predictors of progression-free survival.

Mayr et al. (2002) used MRI scans to evaluate tumor regression at 40–50 Gy of external beam RT combined with chemotherapy in 34 cervical cancer patients. Regression to less than 20% of residual tumor volume resulted in a cumulative incidence of local recurrence of 9.5 vs. 77% in patients with more than 20% residual volume (p < 0.001).

Standardized surveillance programs have proposed the use of routine physical examination and patient’s symptoms education to facilitate early disease detection. However, studies have reported better overall survival in patients with asymptomatic disease recurrence (Bodurka-Bevers et al., 2000). In that setting, the use of FDG-PET/CT in a selected group of patients could potentially lead to a salvage curative therapy of local or oligometastatic disease (Brooks et al., 2009). In a study performed by Mittra et al. (2009), 30 women with locally advanced tumors who had undergone FDG-PET/CT during the surveillance period were evaluated. FDG-PET/CT facilitated the detection of local and distant metastases, with a sensitivity of 93–96% and a specificity of 93–95%. Seventy-one percent of the scans performed in symptomatic patients showed true-positive findings against 44% in asymptomatic patients. This could have significant implications for the use of salvage radiotherapy (Figures 3A–C). Stereotactic radiosurgery has been evaluated in several retrospective studies of metastatic gynecological malignancies and has demonstrated activity at various doses and schedules. Particularly in patients with small tumor burden at recurrence and good performance status, the use of stereotactic body radiation therapy (SBRT) to treat FDG-PET avid para-aortic disease has shown a 4-year local control rate of 67.4%, with low incidence of G3-4 complications (Choi et al., 2009; Kamos et al., 2012a,b). More prospective studies are needed to confirm the role of molecular imaging as a routine examination during the follow-up of these patients (Elk et al., 2010).

RADIOTHERAPY TARGET DEFINITION WITH FDG-PET/CT

The rapid evolution of radiotherapy now makes it possible to deliver HDRs to tumors located near normal structures with explicitly sculpted dose sparing of the normal tissues. Anatomical images have historically been used; however, they lack sensitivity for defining tumor extent, and the capacity to evaluate the biology of the tumor and normal tissue. In this context, the use of anatomical images associated with biological images is essential. Biological images allow mapping of molecular distributions and their surrogates, and can be used to guide external beam radiotherapy. For example, Ma et al. (2011) has shown important tumor volume discrepancies between FDG-PET and MRI probably due to the important geometrical changes in the position of the cervix and corpus uteri as well as variations in bladder and rectal filling. Chan et al. (2008) studied the internal movement of the tumor, cervix, and uterus using weekly cine-MRIs and a point of interest analysis (POI). The fundus POI drifted 1.5 cm caudally during CRT, and the cervical canal 1 cm. As previously stated, pathologic uptake of FDG-PET may modify treatment strategy, either by extending the radiation volumes to the para-aortic area, or by modifying the dose to the affected lymph nodes (Figures 4A–C). Esthappan et al. (2004) proposed dose escalation to 59.4 Gy to the positive para-aortic lymph node and 50.4 Gy to the para-aortic region using CT-PET-guided IMRT. In a series of 208 patients with cervix cancer, lymph nodes were scored as either positive or negative for abnormal FDG uptake PET and lymph node status by CT was classified as < 1 cm (negative) or > 1 cm (positive) (Grigsby et al., 2004). All enlarged lymph nodes detected by CT were PET positive. No patient underwent lymph node dissection. The dose to pelvic lymph nodes was dependent on PET and CT findings. PET negative nodes, <1 cm, 66.8 Gy, and 0/76 failures; PET positive nodes, <1 cm, 66.8 Gy,
and 3/89 failures; 1.1 to <2 cm, 66.9 Gy, and 0/21 failures; 2.1 to <3 cm, 69.4 Gy, and 2/15 failures; and 3.1 to <4 cm, 74.1 Gy, and 0/5 failures. The risk of isolated nodal failure was <2% for tumors ≥10 Gy, and V20 ≥10 Gy, and V30 ≥10 Gy). V20 (volume receiving ≥20 Gy) has been shown to be significantly less with total bone marrow sparing IMRT (Liang et al., 2012). Not only can FDG-PET/CT drive tumor dose painting with IMRT, but it might also help to limit hematological toxicity. In locally advanced cervical cancer treated with CRY, both modalities are myelosuppressive (Green et al., 2001; Bachtiary et al., 2005; Vale et al., 2010). Identifying active bone marrow sub-regions with FDG-PET, and the development of hematological toxicity. IMRT can reduce the dose to bone marrow identified by FDG-PET, and the development of hematological toxicity. IMRT can reduce the dose to bone marrow identified by FDG-PET/CT: the mean functional bone marrow V10 (volume of bone marrow receiving ≥10 Gy), and V20 (volume receiving ≥20 Gy) has been shown to be significantly less with total bone marrow sparing IMRT (Liang et al., 2012).

This has important implications in the development of new therapeutic strategies to treat cervical cancer. A recently published trial identified a survival advantage in patients with locally advanced cervical cancer treated with concurrent gemcitabine, cisplatin, and pelvic radiation with adjuvant gemcitabine and cisplatin compared with concurrent cisplatin and pelvic radiation alone. In this study, more than Grade-3 hematological toxicity occurred in 72% of the experimental arm and was a frequent cause of treatment discontinuation (Duenas-Gonzalez et al., 2011). Several research groups are now focusing on the implementation of phase III trials looking at the potential benefits of adjuvant chemotherapy (NCT01414608). Consequently, reducing radiation-induced bone marrow damage is essential.

ROLE OF FDG-PET IN BRACHYTHERAPY

The use of image-guided brachytherapy has become standard in our clinic as well as many other cancer centers. MRI-guided brachytherapy is the method most frequently used, allowing an accurate tumor delineation and dose optimization. Recommendations have been published to avoid inter-observer variability in the delineation of tumors and organs at risk as well as a reliable definition of target volumes with a common language among centers (Haie-Meder et al., 2005; Potter et al., 2006).

A few studies have assessed the role of FDG-PET-guided brachytherapy. Mahapa et al. (2002) Compared two-dimensional (2D) treatment planning orthogonal radiography-based brachytherapy with 3D treatment planning based on FDG-PET in 11 patients with cervical cancer. The patients underwent two PEIs: a first one to visualize the tumor and a second one with the FGI placed inside the tandem and ovoid applicators to visualize the treatment source positions for 3D treatment planning. The authors concluded that this technique was feasible and accurate relative to 2D treatment planning. Lin et al. (2007) conducted a dosimetric study comparing intracavitary brachytherapy using a...
standard plan with a PET-defined tumor volume in 11 patients undergoing intracavitary treatments. The coverage of the target isodose surface for the first implant with and without optimization was 73 and 68%, respectively (p = 0.21). For the mid and final implant, the coverage was 83 and 79% (p = 0.02). The dose to point A was significantly higher with the optimized plans for both the first implant (p = 0.02) and the mid and last implants (p = 0.008). The dose to the 2 and 5 cm³ of bladder or rectum were not significantly different. The authors concluded that FDG-PET-based treatment planning improved tumor dose coverage without significantly increasing doses to the bladder and rectum. A recent publication by Nam et al. (2012) confirms these results; they evaluated the feasibility of FDG-PET/CT conformal brachytherapy in 12 patients with cervical cancer. Brachytherapy was performed at 41.4 Gy, and the prescribed dose to point A was 4 Gy. The median dose that encompassed 95% of the target volume (D95) of the CTV was 3.33 Gy for point A-2D-based plan vs. 3.99 Gy for the FDG-PET/CT optimized plan. They concluded that
PET/CT conformal brachytherapy was feasible and target coverage was better than conventional point A plans.

ASSESSING TUMOR HYPOXIA BY PET

The most extensively studied biological predictor of response to radiotherapy is hypoxia. Hypoxic cells are more resistant to killing by ionizing radiation and chemotherapy (Brown and Giaccia, 1998).

In general, cervical cancer hypoxia has been associated with more malignant phenotypes (Hockel et al., 1999), higher rates of metastatic disease (Ling et al., 2000; Fyles et al., 2002, 2006), and higher recurrence rates regardless of whether treatment is RT or surgery (Hockel et al., 1996). Hypoxia coupled with abnormal angiogenesis will provoke impaired tumor perfusion and high interstitial fluid pressure (IFP) which has been further linked with worst outcome (Milosevic et al., 2014).

Several hypoxic tracers suitable for PET have received special attention. Fluoromisonidazole (18-FMISO) is the hypoxia tracer most extensively studied (Basey et al., 1987, 1989). However, its major disadvantages refer to its slow clearance kinetics and its high lipophilicity. Another PET tracer under study is 18F-fluorozomycin-arabinoside (18FAZA). The feasibility of 18FAZA was evaluated recently in patients with advanced cervical cancer in a study performed by Schuetz et al. (2010). Fifteen consecutive patients with locally advanced cervical cancer were treated with CIRT. 18FAZA-PET scans were performed before, during and after external beam therapy and image-guided brachytherapy. Five patients had visually identifiable tumors on 18FAZA-PET scans performed prior to therapy, and four patients before brachytherapy. One of five PET positive patients had incomplete remission 3 months after RT, and one had regional recurrence. Four of ten PET negative patients developed distant metastases. The authors concluded that 18FAZA-PET imaging is feasible, however, its predictive and prognostic value in cervical cancer remains to be clarified.

One of the most promising agents currently under study is 64Cu-labeled diacetyl-bis (N7-methylthiosemicarbazone) (64Cu-ATSM). In a preliminary study by Dehdashti et al. (2008), 38 women with locally advanced cervical cancer were evaluated before the initiation of definitive CIRT. 64Cu-ATSM uptake was evaluated semi-quantitatively as the tumor-to-muscle activity ratio (T/M). A log-rang test determined that the T/M cut-off uptake value of >3.5 was significantly associated with worst outcome. Higher uptake of 64Cu-ATSM has been shown to correlate with other biomarkers of tumor hypoxia such as vascular endothelial growth factor receptor (VEGF), epidermal growth factor receptor (EGFR), cyclogenyrase-2, and carbonic anhydrase-IV (Grigsby et al., 2007).

Most clinical copper-ATSM studies have used the agent labeled with the short-lived positron-emitting radionuclide of copper, 60Cu (half-life, 0.395 h; β1-decay, 92.5%; electron capture, 7.5%; 60Dehdashti et al., 2003). To enable copper-ATSM to be translated for use in PET centers that do not have an in-house cyclotron, copper-ATSM labeled with one of the longer-lived positron-emitting nuclides, 64Cu (half-life, 12.7 h; β1-decay, 17.4%; β2-decay, 38.5%; electron capture, 43%) or 61Cu (half-life, 3.33 h; β1-decay, 62%; electron capture, 38%), is required. The longer half-lives of 64Cu and 61Cu allow for production at a regional center and distribution to PET facilities in a fashion similar to that for 18F-labeled radiopharmaceuticals (Blower et al., 1996). 64Cu-labeled diacetyl-dil(N(4)-methylthiosemicarbazone) (64Cu-ATSM) has also been studied in cervical cancer and comparisons with 60Cu-ATSM showed better image quality due to reduced noise. Furthermore the pattern and magnitude of tumor uptake of 64Cu-ATSM and 60Cu-ATSM were similar (Lewis et al., 2008). A multicentre, prospective, phase II study is currently recruiting patients to define the role of pre-therapy 60Cu-ATSM in predicting prognosis and determining the behavior of locally advanced cervical cancer (NCT00794339).

The development of new PET tracers targeting hypoxic response is essential because we are now in the era of rationally designed molecularly targeted therapies combined with CRT, which poses a significant challenge not only in evaluating mixed toxicity profiles but also in the evaluation of tumor response. New molecular targets may work by mechanisms unlikely to cause tumor regression, and there remains an important need to develop biomarkers to provide early evidence of drug activity not only in the tumor but also its vasculature.

ASSESSING TUMOR ANGIOGENESIS BY PET

Targeting the angiogenic pathway is an increasingly important therapeutic strategy for cervix cancer, and recent phase II studies have shown encouraging results (Townsend et al., 2011; Scheffer et al., 2012). The choice of agents and combinations is dependent on understanding the biology of cancer and the availability of anticancer agents and their toxicities. Integrin αvβ3 is up-regulated in both tumor cells and angiogenic endothelial cells, making it an attractive therapeutic target. In recent studies in cervix cancer patients the expression of β3 integrins, had a significant prognostic impact on outcome according to univariate and multivariate analyses (Guber et al., 2005). In another study the expression of αvβ3 in cervix cancer correlated with different clinico-pathological parameters and with worse overall and disease-free survival. Over expression of αvβ3 in cervical squamous carcinomas is an unfavorable prognostic factor. This might reflect an increased capacity of αvβ3-expressing tumor cells to migrate in a fibronectin-rich extra cellular matrix (ECM) and/or to activate TGF-β1 at the tumor/stromal interface, both of which processes may contribute to cervical cancer progression (Hafitz et al., 2007).

Tumor-associated vessels express integrin αvβ3 (Brooks et al., 1994a,b). It is possible that increased expression of integrins αvβ3 and αvβ5 allow angiogenic endothelial cells to bind provisional matrix proteins such as vitronectin, fibrinogen, von willebrand factor, osteopontin and fibronectin that are deposited in the tumor microenvironment. These adhesive interactions could provide survival cues and/or traction for invading endothelial cells. Through genetic deletion, or treatment with integrin antagonists, several additional integrins have been identified as crucial for angiogenesis, including αvβ1, αvβ6, αvβ8, α5β1, α5β3, and αvβ6 (Avraamides et al., 2008).

Cilengitide (EMD 121974, manufactured by Merck KGaA, Darmstadt, Germany) is an investigational cyclic arginine–glycine–aspartic acid (RGD) containing pentapeptide
sequence that selectively inhibits the αvβ3,α5 integrins (Dechantestr
tier et al., 1999). Cilengitide is the first integrin inhibitor to reach
phase III clinical trials in glioblastoma, another highly vascularized
cancer (Reardon et al., 2008a;b; 2011; Mauser et al., 2009; Stupp
et al., 2010). Cilengitide is now being tested in phase II studies in
patients with lung, pancreas, head and neck, and prostate can-
cer, by radiotherapy, and other molecular targeted agents (Reekman et al., 2006; Fries et al., 2006; Ver
morken et al., 2011; Alva et al., 2012).
As a result, better vascular imaging techniques are being
developed to monitor responsiveness to treatment. In particular,
counterable effort has been expended on characterizing integrin
antagonists for their ability to specifically deliver diagnostic agents
to tumor cells and associated blood vessels (123Ga-NO-DAGA-RGD is
one of them, composed of one pentacrylic motif (RGD) and the
68Ga-labeled reagent NO-DAGA. Cyclo-RGD-NO-DAGA peptide is
labelled with 68Ga eluted from a 68Ge/68Ga generator
directly on site (GMP) so as to form the 68Ga-NO-DAGA-
RGD that will be administered to the patient. Dosimetry of
68Ga-NO-DAGA-RGD PET/CT has been extrapolated from mice
(Buchegger et al., 2011), and this radiopharmaceutical agent is
in clinical use in our institution in a Swedish-approved study
(NCT016808516). Our group is now evaluating the possibility
of embarking on a phase I–II study to evaluate toxicity and efficacy
of cilengitide combined with CRT in locally advanced cervical
cancer.

CONCLUSION
There is a high level of evidence that FDG-PET/CT plays an
essential role in the primary evaluation of cervical carcinoma,
particularly in evaluating lymph nodal status and distant metas-
tases, contributing to precise tumor staging and changes in
therapeutic attitudes. In surgical staged patients the diagnostic performance of FDG-
PET/CT has shown a sensitivity of >90%, a specificity of >90% for detecting lymph node metastases.

Position emission tomography – computed tomography has
gained importance in determining prognosis, assessing treatment
treatment response and evaluation of disease recurrence. The use of FDG-
PET/CT is important to accurately define radiotherapy volumes,
particularly in evaluating lymph nodal status and distant metas-
tases (Alva et al., 2012).

ACKNOWLEDGMENT
We thank Ms. Julia Rengers for her advice on language spelling and

REFERENCES
Abu, A., Klein, S., Diagnos, S., Car
ducei, M., Dipaolo, R., Pintus, K.,
et al. (2012). Phase II study of cilend
itide (EMD 121974, NSC 707544) in
patients with non-metastatic contra
st resistant prostate cancer, NCI-
671. In: Proceedings of the 36th annu
al meeting of the American Society
for Prostate cancer clinical trials con
sortium. Jour. New Drug 31, 746–747.
Armstrong, G. J., Garmy-Susini, B.,
and Vernet, A. (2008). Integrins in
angiogenesis and lymphangiogenesis.
Nat Rev Cancer 8, 352–364.
Buckley, B., Desai, A., Pintus, M.,
Seranzonii, J., Ahem, S., Lewin, W.,
et al. (2005). Comparison of lean body mass between continuous low-dose-rate and pulsed-dose brachytherapy in cervical cancer patients. J. Radial Oncol. Bio 43, 1077–1080.
Buckman, W. K., Colen, A. D., Cooney,
K., Dipaolo, R., Douai, R. L., Gross,
et al. (2006). Phase II evaluation of
cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Gentours. Tumor Genet. Cancer Gen 4, 298–302.
Bloore, P. J., Leven, J. S., and Zee
, J. (1996). Copper radionu-
dides and radiopharmaceuticals in
nuclear medicine. Nidol Med Biol 23, 957–980.
Bokhata-Bevers, D., Martice, M., Eifl,
P. J., Levenback, C., Berens, M. W.,
Lucas, K. R., et al. (2008). Posit
-therapy surveillance of women with
cervical cancer: an outcomes analysis.
Gynec. Oncol. 78, 187–193.
Bouganim, M., Luboitzien, S., Rey,
A., Paineau, J. T., Zafiri, Y., Davi
laid, P., et al. (2008). Histologic
results of para-aortic lymphadenec-
ysis in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J. Clin. Oncol. 26, 1986–1992.
Brodo, F. C., Clark, B. A., and Chere
d, D. A. (1994). Requirement of vas-
cular integrin alpha v beta 3 for angiogenesis. Science 264, 569–571.
Brodo, F. C., Montgomery, A. M.,
Rosenthal, M., Reaifield, B. A., Bu,
K., Blain, G., et al. (1994b). Integrin
alpha v beta 3 antagonists promote tumor regression by inducing apopto
sis of angiogenic blood vessels. Calf. 79, 1157–1164.
Brodo, R. A., Rader, J. S., Dehdashti,
D., Martin, D. G., Powell, M. A.,
Thaker, P. H., et al. (2009). Integrin
beta 3 antagonists promote tumor
regression by inducing apoptosis
of angiogenic blood vessels. Cell
79, 1157–1164.
Brown, J. M., and Giaccia, A. J.
(1998). The unique physiology of
solid tumors: opportunities (and
problems) for cancer therapy. Cancer Res. 58, 1489–1496.
Buchegger, F., Voelt, D., Rauchlet, H.,
Dunet, V., Kosinksi, M., Poirry,
Yanne, C., et al. (2011). 68Ga-
NO-DAGA-RGD for alphabetic im-
gration PET imaging. Procedural
investigation and dosimetry. Nuklearmedizin 50, 225–231.
Chan, P., Damouline, R., Hailes, M. A.,
Cho, Y. B., Jaffey, D., Lockwood,
G., et al. (2005). Inter- and infratracti
onal tumor and organ movement in
patients with cervical cancer under
going radiotherapy: a cinematic-MRI
study. Int. J. Radiat. Oncol. Bio 67, 1517–1523.
Che, C. W., Cho, C. H., Yoo, S. Y.,
Kim, M. S., Yang, K. M., Yoo, H. J.,
et al. (2009). Image-guided stereotac
ic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. J. J. Radiat. Oncol. Bio. Phys. 74, 147–155.
Choy, H. H., Chang, T. C., Yen, T. C.,
Ng, K. K., Hsueh, S., Ma, S. Y.,
et al. (2009). Image-guided stereotac
tic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. J. J. Radiat. Oncol. Bio. Phys. 74, 147–155.
Che, H. H., Chang, T. C., Yen, T. C.,
Ng, K. K., Hsueh, S., Ma, S. Y.,
et al. (2009). Image-guided stereotac
tic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. J. J. Radiat. Oncol. Bio. Phys. 74, 147–155.
Duenas-Gonzalez, A., Zarba, J. J.,
Pak, F., Fakour, J. C., Bodia, S.,
Casavulla, E., et al. (2010). Phase III,
open-label, randomized study com
paring concurrent gemcitabine plus
cisplatin and adriamycin followed by
adjuvant gemcitabine and cisplatin

The role of PET/CT in cervical cancer.

“fonc-03-00034” — 2013/2/25 — 18:02 — page 8 — #8

Frontiers in Oncology | Cancer Imaging and Diagnosis
February 2013 | Volume 3 | Article 34 | 8

The role of PET/CT in cervical cancer.

“fonc-03-00034” — 2013/2/25 — 18:02 — page 8 — #8

Frontiers in Oncology | Cancer Imaging and Diagnosis
February 2013 | Volume 3 | Article 34 | 8

The role of PET/CT in cervical cancer.
Ferlay, J., Parkin, D. M., and Steliarova-Herrera and Prior The role of PET/CT in cervical cancer

Fyles, A., Milosevic, M., Hedley, D., Pin-Friess, H., Langrehr, J. M., Oettle, H., Foucher, E. (2010a). Estimates of carcinoma with positive paraaortic CT/PET-guided IMRT for cervical carcinoma of the uterine cervix. Cancer Res 70, 4599–4615.

Grigsby, P., Zoberi, I., Dehdashti, F., et al. (2010b). Clinical outcomes of definitive intensity-modulated radiation therapy with concurrent chemotherapy for pelvic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 78, 2108–2113.

Kidd, E. A., Siegel, B. A., Dehdashti, F., Rader, J. S., et al. (2010a). Lymph node staging by positron emission tomography in cervical cancer: experience of the Gynecologic Oncology Group (I): concepts and terms in interstitial fluid pressure and hypoxia imaging in cervix cancer brachytherapy planning in cervix cancer: primary endpoint analysis of RT0128. Int. J. Radiat. Oncol. Biol. Phys. 81, 97–103.

Kidd, E. A., Siegel, B. A., Dehdashti, F., and Grigby, P. W. (2007). The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer: primary endpoint analysis of RTOG 0128. Int. J. Radiat. Oncol. Biol. Phys. 68, 4525–4532.

Higashikubo, R., Schwarz, J. K., Dittrich, C., et al. (2006). A random of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917.

Kus, A. J., Kara, I. M., Tyrrell, J. P., Symonds, F., Frisco, L., Collingwood, M., et al. (2001). Survival and recurrence after concomitant chemotheraphy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358, 791–798.

Grigby, P. W., Malynn, B. S., Higashikubo, R., Schwartz, J. K., Widch, M. J., Huettman, P. C., et al. (2017). Comparison of molecular markers of hypoxia and imaging with [18F]-FDG-ACT in cancer of the uterine cervix. Med. Imaging Radiol. 9, 278–284.

Widch, M. J., Radoslav-Foucher, E., et al. (2010a). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917.

Grigby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J. S., and Zoberi, I. (2004). Immunohistochemical cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 768–791.

Grigby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J. S., and Zoberi, I. (2004). Immunohistochemical cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 768–791.

Grigby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J. S., and Zoberi, I. (2004). Immunohistochemical cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 768–791.

Grigby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J. S., and Zoberi, I. (2004). Immunohistochemical cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 768–791.

Grigby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J. S., and Zoberi, I. (2004). Immunohistochemical cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 768–791.

Grigby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J. S., and Zoberi, I. (2004). Immunohistochemical cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 768–791.

Grigby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J. S., and Zoberi, I. (2004). Immunohistochemical cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 768–791.

Grigby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J. S., and Zoberi, I. (2004). Immunohistochemical cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 768–791.

Grigby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J. S., and Zoberi, I. (2004). Immunohistochemical cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 768–791.

Grigby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J. S., and Zoberi, I. (2004). Immunohistochemical cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 768–791.

Grigby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J. S., and Zoberi, I. (2004). Immunohistochemical cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 768–791.

Grigby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J. S., and Zoberi, I. (2004). Immunohistochemical cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 768–791.

Grigby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J. S., and Zoberi, I. (2004). Immunohistochemical cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 768–791.

Grigby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J. S., and Zoberi, I. (2004). Immunohistochemical cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 768–791.

Grigby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J. S., and Zoberi, I. (2004). Immunohistochemical cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 768–791.

Grigby, P. W., Singh, A. K., Siegel, B. A., Dehdashti, F., Rader, J. S., and Zoberi, I. (2004). Immunohistochemical cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 58, 768–791.
The role of PET/CT in cervical cancer

Herrera and Prior

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 09 September 2012; accepted: 06 September 2013. doi: 10.3389/fonc.2013.00034

The article was submitted to Frontiers in Cancer Imaging and Diagnosis, a specialty journal of Frontiers in Oncology. Copyright © 2013 Herrera and Prior. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics on the.